Reparación de furca de segundo molar inferior permanente utilizando Agregado de Trióxido Mineral. Presentación de un caso

A consulta acude una paciente femenina de 47 años refiriendo dolor pulsátil que no alivia con analgésico, en hemiarcada inferior izquierda. El examen clínico muestra restauración desplazada y gran recidiva de caries en el 37. Radiográficamente se obseva una lesión en la bifurcación radicular. La paciente anhela conservar su pieza dentaria y se le practica un tratamiento endodóntico tradicional en 3 sesiones. Posterior a esto, se aplica MTA en el piso de la cámara pulpar y se evolucionó a los 5 y 10 días, lo que resultó un procedimiento donde se logró la conservación del diente, con el tratamiento equilibrado y la garantía de una mejor calidad de vida y atención. El presente estudio tiene como objetivo describir la evolución a los 10 días del empleo del Agregado de Trióxido Mineral en esa lesión de furca de un segundo molar permanente inferior izquierdo.ABSTRACTFemale patient of 47 years old comes to the consultation referring sharp pain in left lower side that doesn’t relief with analgesics. On the clinical examination was discovered restoration displaced and large dental caries below of cavity on 37. The x-ray showed injury of furca. The patient reaffirms her desire of keeping her tooth and make a treatment endodontic traditional in 3 times. Then, after applicant MTA in the flat of the pulpar camera and to see the evolutions around 5 to 10 days, resulting in a procedure on which the preservation of the tooth, equilibrate the expectative of treatment and warranty a better style life and attention for our patients. The objective of this study is to show the evolution in 10 days with employ of MTA in a furcal lesion in a permanent lower left second molar

Torus and Active Galactic Nucleus Properties of Nearby Seyfert Galaxies: Results from Fitting Infrared Spectral Energy Distributions and Spectroscopy

We used the CLUMPY torus models and a Bayesian approach to fit the infrared spectral energy distributions and ground-based high angular resolution mid-infrared spectroscopy of 13 nearby Seyfert galaxies. This allowed us to put tight constraints on torus model parameters such as the viewing angle i, the radial thickness of the torus Y, the angular size of the cloud distribution σtorus, and the average number of clouds along radial equatorial rays N0. We found that the viewing angle i is not the only parameter controlling the classification of a galaxy into type 1 or type 2. In principle, type 2s could be viewed at any viewing angle i as long as there is one cloud along the line of sight. A more relevant quantity for clumpy media is the probability for an active galactic nucleus (AGN) photon to escape unabsorbed. In our sample, type 1s have relatively high escape probabilities, Pesc ~ 12%-44%, while type 2s, as expected, tend to have very low escape probabilities. Our fits also confirmed that the tori of Seyfert galaxies are compact with torus model radii in the range 1-6 pc. The scaling of the models to the data also provided the AGN bolometric luminosities Lbol(AGN), which were found to be in good agreement with estimates from the literature. When we combined our sample of Seyfert galaxies with a sample of PG quasars from the literature to span a range of Lbol(AGN) ~ 1043-1047 erg s-1, we found plausible evidence of the receding torus. That is, there is a tendency for the torus geometrical covering factor to be lower (f2 ~ 0.1-0.3) at high AGN luminosities than at low AGN luminosities (f2 ~ 0.9-1 at ~{}1043-1044 erg s-1). This is because at low AGN luminosities the tori appear to have wider angular sizes (larger σtorus) and more clouds along radial equatorial rays. We cannot, however, rule out the possibility that this is due to contamination by extended dust structures not associated with the dusty torus at low AGN luminosities, since most of these in our sample are hosted in highly inclined galaxies

Discovery of inhibitors of protein tyrosine phosphatase 1B contained in a natural products library from Mexican medicinal plants and fungi using a combination of enzymatic and in silico methods**

This work aimed to discover protein tyrosine phosphatase 1B (PTP1B) inhibitors from a small molecule library of natural products (NPs) derived from selected Mexican medicinal plants and fungi to find new hits for developing antidiabetic drugs. The products showing similar IC50 values to ursolic acid (UA) (positive control, IC50 = 26.5) were considered hits. These compounds were canophyllol (1), 5-O-(β-D-glucopyranosyl)-7-methoxy-3′,4′-dihydroxy-4-phenylcoumarin (2), 3,4-dimethoxy-2,5-phenanthrenediol (3), masticadienonic acid (4), 4′,5,6-trihydroxy-3′,7-dimethoxyflavone (5), E/Z vermelhotin (6), tajixanthone hydrate (7), quercetin-3-O-(6″-benzoyl)-β-D-galactoside (8), lichexanthone (9), melianodiol (10), and confusarin (11). According to the double-reciprocal plots, 1 was a non-competitive inhibitor, 3 a mixed-type, and 6 competitive. The chemical space analysis of the hits (IC50 < 100 μM) and compounds possessing activity (IC50 in the range of 100–1,000 μM) with the BIOFACQUIM library indicated that the active molecules are chemically diverse, covering most of the known Mexican NPs’ chemical space. Finally, a structure–activity similarity (SAS) map was built using the Tanimoto similarity index and PTP1B absolute inhibitory activity, which allows the identification of seven scaffold hops, namely, compounds 3, 5, 6, 7, 8, 9, and 11. Canophyllol (1), on the other hand, is a true analog of UA since it is an SAR continuous zone of the SAS map

Evaluación del proceso de revisión de transcripciones automáticas para vídeos Polimedia

[EN] Video lectures are a tool of proven value and wide acceptance in universities that are leading to platforms like poliMedia. transLectures is a European project that generates automatic high-quality transcriptions and translations for the poliMedia platform, and improve them by using massive adaptation and intelligent interaction techniques. In this paper we present the evaluation with lecturers carried out under the Doc`encia en Xarxa 2012-2013 call, with the aim to study the process of supervise transcriptions, compared with to transcribe from scratch.[ES] Los vídeos docentes son una herramienta de demostrada utilidad y gran aceptación en el mundo universitario que están dando lugar a plataformas como poliMedia. transLectures es un proyecto europeo que genera transcripciones y traducciones autom´aticas de alta calidad para la plataforma poliMedia, mediante t´ecnicas de adaptaci´on masiva e interacci´on inteligente. En este art´ıculo presentamos la evaluaci´on con profesores que se realiz´o en el marco de Doc`encia en Xarxa 2012-2013, con el objetivo de estudiar el proceso de supervisi´on de transcripciones, compar´andolo con la obtenci´on de la transcripci´on sin disponer de una transcripci´on autom´atica previa.*The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 287755.Valor Miró, JD.; Nadine Spencer, R.; Pérez González De Martos, AM.; Garcés Díaz-Munío, GV.; Turró Ribalta, C.; Civera Saiz, J.; Juan, A. (2014). Evaluación del proceso de revisión de transcripciones automáticas para vídeos Polimedia. En Jornadas de Innovación Educativa y Docencia en Red de la Universitat Politècnica de València. Editorial Universitat Politècnica de València. 272-278. http://hdl.handle.net/10251/54397S27227

Torus and AGN properties of nearby Seyfert galaxies: Results from fitting IR spectral energy distributions and spectroscopy

We used the CLUMPY torus models and a Bayesian approach to fit the infrared spectral energy distributions (SEDs) and ground-based high-angular resolution mid-infrared spectroscopy of 13 nearby Seyfert galaxies. This allowed us to put tight constraints on torus model parameters such as the viewing angle, the radial thickness of the torus Y, the angular size of the cloud distribution sigma_torus, and the average number of clouds along radial equatorial rays N_0. The viewing angle is not the only parameter controlling the classification of a galaxy into a type 1 or a type 2. In principle type 2s could be viewed at any viewing angle as long as there is one cloud along the line of sight. A more relevant quantity for clumpy media is the probability for an AGN photon to escape unabsorbed. In our sample, type 1s have relatively high escape probabilities, while in type 2s, as expected, tend to be low. Our fits also confirmed that the tori of Seyfert galaxies are compact with torus model radii in the range 1-6pc. The scaling of the models to the data also provided the AGN bolometric luminosities, which were found to be in good agreement with estimates from the literature. When we combined our sample of Seyfert galaxies with a sample of PG quasars from the literature to span a range of L_bol(AGN)~10^{43}-10^{47}erg/s, we found plausible evidence of the receding torus. That is, there is a tendency for the torus geometrical covering factor to be lower at high AGN luminosities than at low AGN luminosities. This is because at low AGN luminosities the tori appear to have wider angular sizes and more clouds along radial equatorial rays. We cannot, however rule out the possibility that this is due to contamination by extended dust structures not associated with the dusty torus at low AGN luminosities, since most of these in our sample are hosted in highly inclined galaxies. (Abridged)Comment: Accepted for publication in Ap

TransLectures

transLectures (Transcription and Translation of Video Lectures) is an EU STREP project in which advanced automatic speech recognition and machine translation techniques are being tested on large video lecture repositories. The project began in November 2011 and will run for three years. This paper will outline the project¿s main motivation and objectives, and give a brief description of the two main repositories being considered: VideoLectures.NET and poliMedia. The first results obtained by the UPV group for the poliMedia repository will also be provided.The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 287755. Funding was also provided by the Spanish Government (iTrans2 project, TIN2009-14511; FPI scholarship BES-2010-033005; FPU scholarship AP2010-4349)Silvestre Cerdà, JA.; Del Agua Teba, MA.; Garcés Díaz-Munío, GV.; Gascó Mora, G.; Giménez Pastor, A.; Martínez-Villaronga, AA.; Pérez González De Martos, AM.... (2012). TransLectures. IberSPEECH 2012. 345-351. http://hdl.handle.net/10251/3729034535

Enabling planetary science across light-years. Ariel Definition Study Report

Ariel, the Atmospheric Remote-sensing Infrared Exoplanet Large-survey, was adopted as the fourth medium-class mission in ESA's Cosmic Vision programme to be launched in 2029. During its 4-year mission, Ariel will study what exoplanets are made of, how they formed and how they evolve, by surveying a diverse sample of about 1000 extrasolar planets, simultaneously in visible and infrared wavelengths. It is the first mission dedicated to measuring the chemical composition and thermal structures of hundreds of transiting exoplanets, enabling planetary science far beyond the boundaries of the Solar System. The payload consists of an off-axis Cassegrain telescope (primary mirror 1100 mm x 730 mm ellipse) and two separate instruments (FGS and AIRS) covering simultaneously 0.5-7.8 micron spectral range. The satellite is best placed into an L2 orbit to maximise the thermal stability and the field of regard. The payload module is passively cooled via a series of V-Groove radiators; the detectors for the AIRS are the only items that require active cooling via an active Ne JT cooler. The Ariel payload is developed by a consortium of more than 50 institutes from 16 ESA countries, which include the UK, France, Italy, Belgium, Poland, Spain, Austria, Denmark, Ireland, Portugal, Czech Republic, Hungary, the Netherlands, Sweden, Norway, Estonia, and a NASA contribution

In-situ estimation of ice crystal properties at the South Pole using LED calibration data from the IceCube Neutrino Observatory

The IceCube Neutrino Observatory instruments about 1 km3 of deep, glacial ice at the geographic South Pole using 5160 photomultipliers to detect Cherenkov light emitted by charged relativistic particles. A unexpected light propagation effect observed by the experiment is an anisotropic attenuation, which is aligned with the local flow direction of the ice. Birefringent light propagation has been examined as a possible explanation for this effect. The predictions of a first-principles birefringence model developed for this purpose, in particular curved light trajectories resulting from asymmetric diffusion, provide a qualitatively good match to the main features of the data. This in turn allows us to deduce ice crystal properties. Since the wavelength of the detected light is short compared to the crystal size, these crystal properties do not only include the crystal orientation fabric, but also the average crystal size and shape, as a function of depth. By adding small empirical corrections to this first-principles model, a quantitatively accurate description of the optical properties of the IceCube glacial ice is obtained. In this paper, we present the experimental signature of ice optical anisotropy observed in IceCube LED calibration data, the theory and parametrization of the birefringence effect, the fitting procedures of these parameterizations to experimental data as well as the inferred crystal properties.</p

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.

BACKGROUND: Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). We investigated whether remote ischaemic conditioning could reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months. METHODS: We did an international investigator-initiated, prospective, single-blind, randomised controlled trial (CONDI-2/ERIC-PPCI) at 33 centres across the UK, Denmark, Spain, and Serbia. Patients (age >18 years) with suspected STEMI and who were eligible for PPCI were randomly allocated (1:1, stratified by centre with a permuted block method) to receive standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5-min inflation and 5-min deflation of an automated cuff device) before PPCI. Investigators responsible for data collection and outcome assessment were masked to treatment allocation. The primary combined endpoint was cardiac death or hospitalisation for heart failure at 12 months in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02342522) and is completed. FINDINGS: Between Nov 6, 2013, and March 31, 2018, 5401 patients were randomly allocated to either the control group (n=2701) or the remote ischaemic conditioning group (n=2700). After exclusion of patients upon hospital arrival or loss to follow-up, 2569 patients in the control group and 2546 in the intervention group were included in the intention-to-treat analysis. At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart failure (the primary endpoint) were 220 (8·6%) patients in the control group and 239 (9·4%) in the remote ischaemic conditioning group (hazard ratio 1·10 [95% CI 0·91-1·32], p=0·32 for intervention versus control). No important unexpected adverse events or side effects of remote ischaemic conditioning were observed. INTERPRETATION: Remote ischaemic conditioning does not improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 12 months in patients with STEMI undergoing PPCI. FUNDING: British Heart Foundation, University College London Hospitals/University College London Biomedical Research Centre, Danish Innovation Foundation, Novo Nordisk Foundation, TrygFonden